Navigation Links
La Jolla Institute-led team illuminates cell pathway key to insulin resistance in Type 2 diabetes
Date:2/24/2011

SAN DIEGO (February 24, 2011) A research team, led by La Jolla Institute scientist Joel Linden, Ph.D., has shed new light on the problem of insulin resistance, and identified the key participants in a molecular pathway that holds therapeutic promise for reducing the severity of type 2 diabetes.

The researchers looked at the role of adenosine, an immune system signaling molecule, in triggering inflammation, which significantly contributes to insulin resistance. Insulin resistance keeps the body from properly handling sugar and is one of the key factors underlying type 2 diabetes. Diabetes now affects nearly 26 million Americans and is the seventh leading cause of death in the U.S., according to the Centers for Disease Control.

"Several previous studies have shown that if you block adenosine signaling, insulin resistance is diminished," said Dr. Linden. "However, it wasn't known exactly how the process worked or which cells were directly involved."

Dr. Linden's team identified the primary cellular players in the adenosine-fueled inflammation cascade that contributes to insulin resistance. Their study, in animal models, also tested the effectiveness of a recently synthesized adenosine receptor blocker. "We found that if you use this molecule to selectively block one of the adenosine receptors, insulin resistance is decreased and diabetes gets better," said Dr. Linden, one of the world's leading authorities on adenosine.

Eugene Barrett, Ph.D., a past president of the American Diabetes Association, praised the study's findings as important. "There is a great need for new approaches to lessen the disease burden caused by insulin resistance," said Dr. Barrett, a professor of medicine and director of the University of Virginia's Diabetes Center, which was not involved in the study. "The work of Dr. Linden and his collaborators opens a new avenue to explore with possibly important therapeutic implications."

The f
'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery
2. La Jolla Institute discovers novel tumor suppressor
3. Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award
4. La Jolla Institute scientist leads team which discovers important new player in diabetes onset
5. La Jolla Institute scientist Klaus Ley receives Malpighi award
6. La Jolla Institute validates Type 1 diabetes computer models predictive success through lab testing
7. Discovery of stem cell illuminates human brain evolution, points to therapies
8. Tiny laser light show illuminates quantum computing
9. New imaging advance illuminates immune response in breathing lung
10. Breast cancer treatment resistance linked to signaling pathway
11. Barcelona Declaration 2008: Challenges and Pathways to Earth Sustainability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2014)... to blame for significant baseline levels of arsenic in ... in the Journal of Environmental Quality . , ... of Ohio showed that every single sample had concentrations ... the U.S. Environmental Protection Agency. The findings should not ... regulatory levels typically are set far below those thought ...
(Date:4/15/2014)... and energy for nearly all life on Earth, yet ... example, little is known about how it is regulated ... we do not know the full list of the ... any organism. , , A type of single-cell green ... subject for photosynthesis research. Despite its importance in the ...
(Date:4/15/2014)... Worcester, Mass. Diana Lados, associate professor ... (WPI) and founding director of the university,s ... two major career achievement awards from leading ... in Detroit, SAE International, a global association ... technical experts in the automotive, aerospace, and ...
Breaking Biology News(10 mins):Significant baseline levels of arsenic found in Ohio soils are due to natural processes 2Significant baseline levels of arsenic found in Ohio soils are due to natural processes 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 4WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 2WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 3WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 4WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 5
... Jerusalem, November 21, 2010 Research work carried out ... warning in the growing field of the development of ... patients through replacement of diseased or damaged tissues by ... a possible danger of cancerous tissue development in the ...
... Consortium (IVCC) has received $50 million from the Bill ... develop new insecticides for the improved control of mosquitoes ... neglected tropical diseases. IVCC was established ... over five years from the foundation. Since then, ...
... prompts normal cells to transform themselves into cancerous cells? Researchers ... Antonio, have identified factors in the very first step of ... tube. The latter accomplishment was reported Sunday [Nov. 21] in ... The DNA molecule the elegant, twin-stranded necklace of ...
Cached Biology News:Hebrew University research carries cautionary warning for future stem cell applications 2Hebrew University research carries cautionary warning for future stem cell applications 3
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 ... today announces Michelle Detwiler as the new Director of ... current and potential clients as well as iLab sub-teams ... main goal will be to ensure that iLab provides ... offering the most advanced, user-friendly, and high-impact solution in ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014 ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that ... the United States Patent and Trademark Office ... for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, ... management ( SCM ) and sales and operations planning ... gold sponsor of the Biomanufacturing Summit , which ... January 30 – 31, 2014.  At the conference, join ... Chain at Amgen, as she presents ,Supply Chain: Improving ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental products, ... dual arch impressions on its dental blog. , ... entry serves up a list of tips to help dentists ... Dr. David Little as he crafts a porcelain crown using ... as the dual arch dental impression material . ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Pressure BioSciences, Inc. (Nasdaq: PBIO ) ... announced that they have entered into a strategic marketing, ... the Agreement, the companies will: (1) share market data, ... certain products at industry trade shows beginning in 2009; ...
... http://www.wellcentive.com ),today announced the launch of two new ... securely and cost-effectively share patient,data within a community ... such as physicians, to easily access patient data ... Connect is a health care technology platform,which receives ...
... NEW YORK, Dec. 11 Delcath Systems, Inc. (Nasdaq: ... its proprietary Percutaneous Hepatic Perfusion ("PHP") System for the treatment ... fifty percent (46 of 92) of patients have been enrolled ... ocular melanoma to the liver. The eleven participating cancer ...
Cached Biology Technology:Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 2Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 3Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 4Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 5WellCentive Launches New Health Information Exchange Platforms 2WellCentive Launches New Health Information Exchange Platforms 3Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 2Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 3
Mouse monoclonal antibody raised against a partial recombinant ZNF167. NCBI Entrez Gene ID = ZNF167...
... HDAC8 Regulation of gene expression ... as DNA methylation, ATP-dependent chromatin remodeling, ... which include the dynamic acetylation and ... residues present in the tail of ...
... raised against a partial recombinant ... SLC22A3 (NP_068812, 90 a.a. ... protein with GST tag. ... NM_021977 Protein ...
...
Biology Products: